Post Profile

Denmark's Genmab looks to immunotherapy for cancer drug encore

LONDON (Reuters) - Immunotherapy, which boosts the immune system to fight cancer, could be the next big opportunity for Genmab, potentially driving peak sales of its top-selling drug well past $10 billion a year, its chief executive believes.
read more


Related Posts

Hot Money Exiting Emerging Assets Is Buy Trigger for Maersk CEO

Vehicles / Watercraft : gCaptain

March 3 (Bloomberg) — A.P. Moeller-Maersk A/S, Denmark’s biggest company, is using a slump in emerging markets as an opportunity to invest, Chief Executive Officer Nils Smedegaard Andersen said. “When [...] The post Hot Money Exitin...

Maersk utilises slump to invest

Business & Finance : Business Report

AP Moller-Maersk, Denmark’s biggest company, was using a slump in emerging markets as an opportunity to invest, chief executive Nils Smedegaard Andersen said in an interview on Monday. ||| Copenhagen - AP Møller-Maersk, Denmark’s bi...

Type 1 diabetes in mice averted with cancer drug

Health : Medical News Today

A new international study led by the University of Copenhagen in Denmark has taken a significant step toward the prevention of type 1 diabetes, by showing how low doses of a cancer drug stopped it developing in disease-prone mice.Th...

Eurozone Boosts Bailout Fund to $1 Trillion

Business & Finance : The Curious Capitalist

COPENHAGEN, Denmark  — The 17 countries that use the euro will put up €500 billion ($670 billion) in fresh money to help countries with debt troubles — a big increase from the previous €300 billion limit, but unlikely to calm concer...

Important Pathway Mapped In The First Line Of Immune Defence; Could Have Implications For The Treatment Of Stroke And Cancer Patients

Health : Medical News Today

Researchers from Aarhus University, Denmark, have now discovered an important mechanism behind one of our most fundamental lines of immune function. The discovery has been published in the esteemed scientific journal, The Journal of...


Copyright © 2016 Regator, LLC